Promoting the removal of pathological tau via microglia or through intracellular degradation pathways like the proteasome. Key Therapeutic Strategies
The concept of "tauons" arises from the observation that misfolded tau protein isoforms can propagate through the brain in a characteristic pattern, similar to prions, driving the progression of conditions like Alzheimer's disease. Antitauon therapies aim to intervene in this process through several key mechanisms: antitauon
While many antitauon therapies have reached clinical trials, results have been mixed: Promoting the removal of pathological tau via microglia
Current research focuses on both to combat these tauon species: Example Agents / Trials Passive Immunotherapy ACI-35 Intracellular Targeting
Administration of lab-made monoclonal antibodies (mAbs) to target specific tau epitopes. , Semorinemab , Gosuranemab Active Immunotherapy
Vaccines that stimulate the patient's own immune system to produce anti-tau antibodies. , ACI-35 Intracellular Targeting